Innere Medizin (Heidelberg, Germany)最新文献

[Update coronary artery disease]. [更新冠状动脉疾病]。

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-05-08 DOI: 10.1007/s00108-026-02118-0

Sven Wassmann

引用次数: 0

[Potassium substitution: is replacing sodium with potassium-enriched salts beneficial?] 钾替代：用富钾盐代替钠有益吗？］

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-05-05 DOI: 10.1007/s00108-026-02112-6

Felix Götzinger, Michael Kunz, Lucas Lauder, Felix Mahfoud

{"title":"[Potassium substitution: is replacing sodium with potassium-enriched salts beneficial?]","authors":"Felix Götzinger, Michael Kunz, Lucas Lauder, Felix Mahfoud","doi":"10.1007/s00108-026-02112-6","DOIUrl":"https://doi.org/10.1007/s00108-026-02112-6","url":null,"abstract":"Background: Hypertension is the leading cause of premature death globally, and acute decompensated heart failure is among the most common causes of hospitalization. Both conditions are adversely affected by high dietary sodium intake. In contrast, potassium has been shown to lower blood pressure. Substituting dietary sodium with potassium may therefore reduce morbidity and mortality associated with hypertension and possibly heart failure.Objectives: This review summarizes the current evidence on the cardiovascular effects of dietary sodium and potassium-containing salts.Current data: Epidemiological studies consistently demonstrate that high sodium intake is associated with elevated blood pressure and increased rates of cardiovascular morbidity and mortality. Meta-analyses indicate that reducing sodium intake lowers blood pressure and reduces cardiovascular events. In a cluster-randomized trial, partial substitution of sodium chloride with potassium-enriched salt reduced cardiovascular morbidity and mortality in patients with hypertension. However, robust data on the effects of sodium restriction or potassium substitution on hard cardiovascular outcomes in patients with heart failure remain limited.Conclusions: High sodium intake has detrimental effects on cardiovascular health. Substituting sodium with potassium-containing salts represents a promising strategy to reduce morbidity and mortality associated with hypertension.","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Applications of artificial intelligence for efficient hospital processes : From hype to clinical relief]. [人工智能在高效医院流程中的应用：从炒作到临床缓解]。

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-05-05 DOI: 10.1007/s00108-026-02122-4

Markus Mandrella, Rudolf Dück, Jens Scholz

引用次数: 0

[Myelofibrosis: watch and wait or treat?] 骨髓纤维化：观察等待还是治疗？］

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-05-01 Epub Date: 2025-12-02 DOI: 10.1007/s00108-025-02021-0

Martin Griesshammer

引用次数: 0

Erratum zu: Neue antimikrobielle Substanzen gegen zunehmende Resistenzen. 抗菌素耐药性增加。

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-05-01 DOI: 10.1007/s00108-026-02100-w

Jasmin Tischer, Nadine Dietze, Kathrin Marx, Henning Trawinski, Christoph Lübbert

引用次数: 0

[Treatment principles and long-term management of glomerulonephritides]. 【肾小球肾炎的治疗原则及长期管理】。

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-05-01 Epub Date: 2026-04-07 DOI: 10.1007/s00108-026-02107-3

Svjetlana Lovric, Stefanie Walter

{"title":"[Treatment principles and long-term management of glomerulonephritides].","authors":"Svjetlana Lovric, Stefanie Walter","doi":"10.1007/s00108-026-02107-3","DOIUrl":"10.1007/s00108-026-02107-3","url":null,"abstract":"Background: Glomerulonephritides (GNs) are a heterogeneous group of mostly immune-mediated kidney diseases and are among of the most common causes of chronic renal failure, including end-stage renal disease. Advances in pathophysiology, histopathology, and immunotherapy have led to more differentiated therapeutic approaches.Aim of the study: To present evidence-based treatment principles and concepts for long-term care in primary and secondary GNs, with particular reference to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.Materials and methods: Review based on international guidelines (KDIGO), national guidelines, randomized controlled trials, meta-analyses, and current publications.Results: The treatment of glomerular diseases is based on a combination of supportive measures, disease-specific immunosuppression, and adjuvant therapy (e.g., lipid, anticoagulation, and vaccination management), as well as structured, long-term care. New pathogenesis-oriented therapies, in particular complement inhibitors and B cell-targeted strategies, are expanding the therapeutic spectrum and enabling low-steroid or steroid-free concepts.Discussion: The long-term prognosis for GN patients depends largely on early diagnosis, correctly stratified initial therapy, consistently implemented supportive measures, close follow-up care, and lifelong nephrological care. Supportive measures are at least as relevant to prognosis as specific immunosuppression. Controversy exists in particular regarding the intensity, duration, and sequence of immunosuppressive therapy, as well as the cost-effectiveness of new biological and complement-targeted substances.","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":" ","pages":"532-538"},"PeriodicalIF":0.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147629464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Einführung zum Thema Glomerulonephritiden – differenzierte Diagnostik und moderne Therapiestrategien. 肾小球肾炎导论：差异化诊断和现代治疗策略。

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-05-01 Epub Date: 2026-04-30 DOI: 10.1007/s00108-026-02109-1

Kai Schmidt-Ott, Roland Schmitt

引用次数: 0

[Primary glomerulonephritides]. [主要glomerulonephritides]。

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-05-01 Epub Date: 2026-03-25 DOI: 10.1007/s00108-026-02102-8

Elion Hoxha

{"title":"[Primary glomerulonephritides].","authors":"Elion Hoxha","doi":"10.1007/s00108-026-02102-8","DOIUrl":"10.1007/s00108-026-02102-8","url":null,"abstract":"Primary glomerulonephritides are inflammatory diseases primarily targeting the glomeruli. Clinically, patients may present with glomerular hematuria and a nephritic urinary sediment and/or with high levels of proteinuria and nephrotic syndrome. Arterial hypertension is also frequently observed in these patients. Although these diseases often lead to loss of renal function, clinical symptoms may be very mild, or even absent in the early stages. Early diagnosis and timely initiation of therapy are therefore of paramount importance. Urinalysis for the detection of glomerular hematuria (by means of urine dipstick and urinary sediment) and proteinuria represents a simple yet highly relevant diagnostic tool for the identification of affected patients. Therefore, such screening procedures should be performed whenever even a minimal suspicion of glomerular disease exists. Although all primary glomerulonephritides primarily affect the glomeruli, the pathogenesis of the various entities-IgA nephropathy, membranous nephropathy, minimal change disease, and primary focal and segmental glomerulosclerosis-differs substantially. Moreover, considerable interindividual variability in disease course and prognosis is observed even within the same diagnostic entity. Therefore, the decision of whether and when to initiate immunosuppressive therapy needs to be individualized, taking into account the risk of disease progression and prognosis. Due to the significant differences in pathogenesis, progression risk, and prognosis between the different forms of glomerulonephritis, as well as within each disease entity, and given the complexity of treatment strategies, patients with primary glomerulonephritis require specialized care in centers with experience in the treatment of these diseases. In recent years, major advances have been made in elucidating the pathomechanisms of primary glomerulonephritides, leading to significant improvements in diagnostic and therapeutic options. Nonetheless, early diagnosis remains a central objective in order to enable targeted and effective treatment and to improve long-term renal outcomes.","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":" ","pages":"499-505"},"PeriodicalIF":0.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147517073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[When AIHA does not explain everything: parvovirus B19 infection and pancytopenia as a differential diagnostic challenge]. [当AIHA不能解释一切：细小病毒B19感染和全血细胞减少症作为鉴别诊断挑战]。

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-05-01 Epub Date: 2025-11-25 DOI: 10.1007/s00108-025-02018-9

W Harms, R Akdas, C Jacob, J Schanz, G Wulf, N Brökers

引用次数: 0

[Approach to suspected glomerulonephritis]. [疑似肾小球肾炎的入路]。

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-05-01 Epub Date: 2026-03-27 DOI: 10.1007/s00108-026-02104-6

Laura Katharina Sievers

引用次数: 0